Boutros R and Byrne JA (2005). D53 (TPD52L1) is a cell cycle regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp. Cell Res. 310: 152-165.

Byrne JA , Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew Y-E, Livnat Y, St. Heaps L, Peters G, Byth K, Karlan BY, Slamon DJ, Harnett P, and deFazio A (2005). Tumor Protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int. J. Cancer 117: 1049-1054.

Tiacci E, Orvietani P-L, Bigerna B, Pucciarini A, Liso A, Pacini R, Verducci B, Pulford K, Pileri S, Gambacorta M, Carbone A, Benedetti R, Sciurpi MT, Binaglia L, Byrne JA , and Falini B (2005). A new monoclonal antibody (b-28p) identifies the human tumor protein D52 (TPD52) as a novel B-cell/ plasma cell associated molecule with a unique expression pattern. Blood 105: 2812-2820.

Byrne JA (2006). Tumor protein D52l2. AfCS-Nature Molecule Pages, doi:10.1038/mp.a000074.01.

Byrne JA (2006). Tumor protein D52l1. AfCS-Nature Molecule Pages, doi:10.1038/mp.a000073.01.

Byrne JA (2006). Tumor protein D52. AfCS-Nature Molecule Pages, doi:10.1038/mp.a000072.01. Journal not indexed by ISI.

Barbaric D, Byth K, Dalla-Pozza L and Byrne JA (2006). Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations. Leukemia Res. 30: 1355-1363.

Lewis JD, Payton LA, Whitford JG, Byrne JA , Smith DI, Yang LB, and Bright RK (2007). Induction of tumorigenesis and metastasis by the murine orthologue of Tumor protein D52 (TPD52). Mol. Cancer Res. 5: 133-144.

Payton LA, Lewis JD, Byrne JA , and Bright RK (2007). Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol. Immunother. 57:799-811.

Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, and Byrne JA (2008). Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin. Cancer Res. 14: 5050-5060.

Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, and Byrne JA (2008). Tumor protein D52 overexpression and gene amplification in cancer- from a mosaic of microarrays. Crit. Rev. Oncogenesis 14: 33-55.

Weidenhofer J and Byrne JA (2009). Isolation of nucleic acids from hard tissues. In: Handbook of Nucleic Acid Purification. Liu D. (Ed.), Taylor & Francis CRC Press, pp. 427-448.

Fanayan S, Shehata M, Agterof AP, McGuckin MA, Alonso MA, and Byrne JA (2009). Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biol 10: 7.

Lewis JD, Sullivan LA, Byrne JA , de Riese W, and Bright RK (2009). Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol. Immunother., epub ahead of print.

Alagaratnam S, Hardy JR, Lothe RA, Skotheim RI, and Byrne JA (2008). TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Mol Cell Endocrinol., epub ahead of print.